Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Paul Vancutsem"'
Autor:
Paul Vancutsem, Marc DeCristofaro, Salah-Dine Chibout, Armin Wolf, Tao Wang, M. Craig Keselica, Francois Pognan, Marion Wiesmann, Elizabeth Skuba, Maria Papoutsi, Judit Markovits, Robert H. Spaet, James Sutton, Pierre Moulin, William Kluwe, Lew Petryk
Publikováno v:
International Journal of Toxicology. 30:300-312
This article addresses the issue of miscorrelation between hepatic injury biomarkers and histopathological findings in the drug development context. Our studies indicate that the use of toxicogenomics can aid in the drug development decision-making p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1062438dffe42d85f393c4f2612c2ecb
https://doi.org/10.1177/1091581811401920
https://doi.org/10.1177/1091581811401920
Autor:
Alessia Petrocchi, Naphtali J. Reyna, Faika Mseeh, Connor A. Parker, Simon Yu, Quanyun Xu, Ningping Feng, Paul Leonard, Norma Rogers, Jason B. Cross, Angela L. Harris, Yongying Jiang, Tin Oo Khor, Mikhila G. Mahendra, Jihai Pang, Qi Wu, Andy M. Zuniga, Timothy McAfoos, Matthew M. Hamilton, Joe R. Marszalek, Keith Mikule, Paul Vancutsem, Keith Wilcoxen, Martin Tremblay, Philip Jones, Richard T. Lewis
Publikováno v:
Cancer Research. 78:LB-071
Indoleamine 2,3-dioxygenase (IDO1 and IDO2) and tryptophan dioxygenase (TDO) are heme-containing enzymes that mediate the rate limiting step in the oxidative degradation of L-tryptophan (L-TRP) to kynurenine (KYN) metabolites. Tryptophan catabolism t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c0efdf3558a82bc49107b3bec62cbd8
https://doi.org/10.1158/1538-7445.am2018-lb-071
https://doi.org/10.1158/1538-7445.am2018-lb-071
Autor:
Kaiming Sun, Paul Vancutsem, Jing Yu Wang, Grace Poon, Sridhar Ramaswamy, Sarah Wang, Jeffrey Hanke
Publikováno v:
Molecular Cancer Therapeutics. 17:A102-A102
Introduction: Niraparib is an orally bioavailable and selective poly (ADP-ribose) polymerase (PARP)-1/-2 inhibitor approved for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::212280a2315f7c93da8cbe5703929f60
https://doi.org/10.1158/1535-7163.targ-17-a102
https://doi.org/10.1158/1535-7163.targ-17-a102
Autor:
Paul Vancutsem, GaryM. Williams
Publikováno v:
The Lancet. 342:873-874
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::babc5665bfac281c14992b87a516f4e5
https://doi.org/10.1016/0140-6736(93)92736-d
https://doi.org/10.1016/0140-6736(93)92736-d